BACKGROUND
The importance of new immuno-oncology medicinal products such as pembrolizumab and nivolumab is increasing drastically from both the therapeutic and the economic point of view. Due to their numerous indication extensions, more patient groups may benefit from them while payers are facing increasing prescription quantities. Moreover, this phenomenon of new indications (± indication extensions) and the corresponding negotiations for the reimbursement price in Germany is not restricted to immuno-oncology medicinal products, but is observed in other therapeutic fields as well. It is to be expected that the National Association of Statutory Health Insurance Funds (SHI/"GKV-Spitzenverband") lowers reimbursement prices to offset the increased number of prescriptions.

RESULTS

- 31 medicinal products that had undergone AMNOG assessment with at least one indication extension were identified (75 procedures in total).
- For 24 medicinal products, indication extensions resulted in a further price decline independent from their category of additional benefit compared to previous assessment outcomes.
- Indication extensions for 4 drugs resulted in an increase of the negotiated reimbursement price for the first assessed indication. An exceptional case is the price increase of fingolimod, since the reimbursement price was determined by the German arbitration board in consideration of re-assessment of previous indication extensions.
- In 3 cases (eribulin, crizotinib, insulin degludec), prices remain stable with 1 indication extension each (category of additional benefit is constant or higher).
- For 24 medicinal products, indication extensions resulted in a further price decline independent from their category of additional benefit compared to previous assessment outcomes.
- 31 medicinal products that had undergone AMNOG assessment with at least one indication extension were identified (75 procedures in total).

CONCLUSIONS
The analysis demonstrates that new indications generally lead to a further price decline, irrespective of the result of the new assessment. Therefore, other factors (comparator costs, costs of comparable drugs, epidemiology, quantity development) may presumably be of higher importance.

REFERENCES
- National Association of Statutory Health Insurance Funds (SHI/"GKV-Spitzenverband") [Internet]: Overview of all price negotiations on the online presence of the "GKV-Spitzenverband" (only available in German, last modified on Sep 14th, 2018, last accessed: Oct 10th, 2018); https://gkv-spitzenverband.de/krankenversicherung/azneimittel/verhandlungen_nach_amnog/bev_130b/bev_verhandlungen_nach_amnog_bev_130b.jsp
- The Federal Joint Committee ("Gemeinsamer Bundesausschuss/G-BA") [Internet]: Overview of resolutions to benefit assessments (only German version up-to-date, last modified on Oct 1st, 2018, last accessed: Oct 10th, 2018); https://www.g-ba.de/informationen/nutzenbewertung/
- Initial prices and reimbursement prices were taken from: "ABDATA Pharma-Daten-Service der Werbe-Vertriebsgesellschaft Deutscher Apotheker (WvU), ABDA-Artikelstamm": https://go.pharmazie.com/en/portfolio-item/drug-pricing-germany-tool/